Exhaled biomarkers in COPD: their potential role in diagnosis, treatment and prognosis.
Several diagnostic tools have been developed for diagnosing, monitoring and evaluating Chronic Obstructive Pulmonary Disease (COPD). There is an increasing interest in the use of non or less invasive biological markers (biomarkers) which reflect the character and intensity of the pathological processes in the lungs of COPD patients. The main goal of this review was to discuss the origin and current role of exhaled biomarkers in the diagnosis, evaluation of treatment and prognosis of COPD. Data of cross-sectional, cohort and intervention studies on exhaled biomarkers were studied. These studies were identified by a Medline search on papers in the English language published from 1990 to November 2001. The following markers were discussed: exhaled nitric oxide (NO), exhaled carbon monoxide (CO), exhaled alkanes, exhaled hydrogen peroxide (H2O2), exhaled isoprostanes, exhaled NO metabolites and exhaled thiobarbituric acid-reactive substances (TBARs). Data on these markers were summarized. The origin of each marker, the technique of analysis, the values in healthy controls and COPD patients, the effect of treatment and the correlation with other parameters were presented. Most studies, however, were cross-sectional studies with small populations. It was also difficult to compare studies because of differences in technique and study population. This review shows that exhaled biomarkers need to be studied further before using them in clinical practice. There is a need for standardization of the measurements, for comparison of COPD patients with healthy persons matched for age and smoking-status, for data on reproducibility and variability of all markers, for correlation of exhaled markers with other parameters and for intervention studies.